The Mucosal Vaccine Adjuvant LT(R192G/L211A) or dmLT
Open accessThe DOI matches its Crossref record; 92 of the 92 references it cites were found in a registry or an index.
Abstract
Perhaps the best-studied mucosal adjuvants are the bacterially derived ADP-ribosylating enterotoxins. This adjuvant family includes heat-labile enterotoxin of Escherichia coli (LT), cholera toxin (CT), and mutants or subunits of LT and CT.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Interestingly, a double-mutant labile toxin (dmLT) derived from Escherichia coli is a potent adjuvant that can enhance immune responses to IPV [113,114,115,116].”
From The Fight against Poliovirus Is Not Over (2023) · cites this paper as [114]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Doreau, A., Belot, A., Bastid, J., Riche, B., Trescol-Biemont, M.-C., Ranchin, B., Fabien, N., Cochat, P., Pouteil-Noble, C., Trolliet, P., et al. (2009) · Nature Immunology · doi:10.1038/ni.1741 · Cited by 452
RetractedTrained immunity: A program of innate immune memory in health and– disease
Netea, M. G., Joosten, L. A. B., Latz, E., Mills, K. H. G., Natoli, G., Stunnenberg, H. G., O’Neill, L. A. J., & Xavier, R. J. (2016) · Science · doi:10.1126/science.aaf1098 · Cited by 2,768
Use of the Inactivated Intranasal Influenza Vaccine and the Risk of Bell's Palsy in Switzerland
Mutsch, M., Zhou, W., Rhodes, P., Bopp, M., Chen, R. T., Linder, T., Spyr, C., & Steffen, R. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa030595 · Cited by 916
New knowledge on pathogenesis of bacterial enteric infections as applied to vaccine development
Levine, M. M., Kaper, J. B., Black, R. E., & Clements, M. L. (1983) · Microbiological Reviews · doi:10.1128/mmbr.47.4.510-550.1983 · Cited by 636
Intestinal ion transport and the pathophysiology of diarrhea
Field, M. (2003) · Journal of Clinical Investigation · doi:10.1172/jci18326 · Cited by 572
Proinflammatory T helper type 17 cells are effective B-cell helpers
Mitsdoerffer, M., Lee, Y., Jäger, A., Kim, H.-J., Korn, T., Kolls, J. K., Cantor, H., Bettelli, E., & Kuchroo, V. K. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1009234107 · Cited by 534
Interleukin 17 is a chief orchestrator of immunity
Veldhoen, M. (2017) · Nature Immunology · doi:10.1038/ni.3742 · Cited by 475
Generalized systemic and mucosal immunity in mice after mucosal stimulation with cholera toxin.
Elson, C. O., & Ealding, W. (1984) · The Journal of Immunology · doi:10.4049/jimmunol.132.6.2736 · Cited by 444
Dickinson, B. L., & Clements, J. D. (1995) · Infection and Immunity · doi:10.1128/iai.63.5.1617-1623.1995 · Cited by 350
Self-citationClements, J. D., & Finkelstein, R. A. (1979) · Infection and Immunity · doi:10.1128/iai.24.3.760-769.1979 · Cited by 330
Self-citation
Research works printed but not linked: 2
- Oplinger ML, Baqar S, Trofa AF, Clements JD, Gibbs P, Pazzaglia G, Bourgeois AL, Scott DA 1997 Safety and immunogenicity in volunteers of a new candidate oral mucosal adjuvant, LT(R192G), p 193 Abstr 37th Intersci Conf Antimicrob Agents Chemother. American Society for Microbiology, Washington, DC.
- Tribble DR, Baqar S, Thompson SA 2008 Development of a human vaccine, p 429– 444. In Nachamkin I, Szymanski CM, Blaser MJ (ed), Campylobacter, 3rd ed ASM Press, Washington, DC.
Cited by
Items 101–183 of 183
Sahoo, A., Jones, A., Cheedarla, N., Gangadhara, S., Roy, V., Styles, T. M., Shiferaw, A., Walter, K. A., Williams, L. D., Shen, X., et al. (2022) · Science Immunology · doi:10.1126/sciimmunol.abl4102 · Cited by 11
Self-citationAnti-Cocaine IgA Rather Than IgG Mediates Vaccine Protection from Cocaine Use
Kosten, T. R., Haile, C. N., Domingo, C. B., & Norton, E. B. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14112368 · Cited by 11
Self-citationZhou, S., Yu, K. O. A., Mabrouk, M. T., Jahagirdar, D., Huang, W., Guerra, J. A., He, X., Ortega, J., Poole, S., Hall, E. R., et al. (2023) · Biomedical Journal · doi:10.1016/j.bj.2023.03.001 · Cited by 12
Non-Invasive Vaccines: Challenges in Formulation and Vaccine Adjuvants
Han, S., Lee, P., & Choi, H. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15082114 · Cited by 13
O’Dowd, A., Maciel, M., Poole, S., Jobling, M. G., Rollenhagen, J. E., Woods, C. M., Sincock, S. A., McVeigh, A. L., Gregory, M. J., Maves, R. C., et al. (2020) · Infection and Immunity · doi:10.1128/iai.00252-20 · Cited by 11
Mottram, L., Lundgren, A., Svennerholm, A., & Leach, S. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.647873 · Cited by 12
Berzosa, M., Nemeškalová, A., Zúñiga-Ripa, A., Salvador-Bescós, M., Larrañeta, E., Donnelly, R. F., Gamazo, C., & Irache, J. M. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14020239 · Cited by 12
Gutiérrez, R. L., Riddle, M. S., Porter, C. K., Maciel, M., Poole, S., Laird, R. M., Lane, M., Turiansky, G. W., Jarell, A. D., & Savarino, S. J. (2023) · Microorganisms · doi:10.3390/microorganisms11112689 · Cited by 10
Das, S., Howlader, D. R., Lu, T., Whittier, S. K., Hu, G., Sharma, S., Dietz, Z. K., Ratnakaram, S. S. K., Varisco, D. J., Ernst, R. K., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1208848 · Cited by 10
L-DBF Elicits Cross Protection Against Different Serotypes of Shigella spp
Lu, T., Das, S., Howlader, D. R., Zheng, Q., Ratnakaram, S. S. K., Whittier, S. K., Picking, W. D., & Picking, W. L. (2021) · Frontiers in Tropical Diseases · doi:10.3389/fitd.2021.729731 · Cited by 10
Jobling, M. G., Poole, S., Rasulova-Lewis, F., O’Dowd, A., McVeigh, A. L., Balakrishnan, A., Sincock, S. A., Prouty, M. G., Holmes, R. K., & Savarino, S. J. (2020) · PLoS ONE · doi:10.1371/journal.pone.0230138 · Cited by 10
Enterovirus Antibodies: Friends and Foes
Mbani, C. J., Morvan, C., Nekoua, M. P., Debuysschere, C., Alidjinou, E. K., Moukassa, D., & Hober, D. (2024) · Reviews in Medical Virology · doi:10.1002/rmv.70004 · Cited by 9
Respiratory mucosal vaccines: Applications, delivery strategies and design considerations
Shi, T., Ye, Y., Fan, Z., Yang, Q., Ma, Y., & Zhu, J. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.118326 · Cited by 9
Berndsen, Z. T., Akhtar, M., Thapa, M., Vickers, T. J., Schmitz, A. J., Torres, J. L., Baboo, S., Kumar, P., Khatoon, N., Sheikh, A., et al. (2024) · PLoS Pathogens · doi:10.1371/journal.ppat.1012241 · Cited by 10
Terán-Navarro, H., Salcines-Cuevas, D., Calderón-González, R., Tobes, R., Calvo, J., Bernal, I. C. P. D. M., Yáñez‐Díaz, S., Fresno, M., & Alvarez-Domínguez, C. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.632304 · Cited by 11
Mucosal vaccination clears Clostridioides difficile colonization
Thomas, A. K., Peritore‐Galve, F. C., Ehni, A. G., Lança, B. B. C., Coggin, J., Brady, E. J., Yoder, S. M., Shrem, R. A., Rodríguez, R. C., Kroh, H. K., et al. (2026) · Nature · doi:10.1038/s41586-026-10138-x · Cited by 8
Stone, A. E., Rambaran, S., Trinh, I., Estrada, M., Jarand, C. W., Williams, B. S., Murrell, A. E., Huerter, C. M., Bai, W. H., Palani, S., et al. (2023) · Vaccine · doi:10.1016/j.vaccine.2023.01.033 · Cited by 8
Self-citationStability Studies of the Vaccine Adjuvant U-Omp19
Darriba, M. L., Cerutti, M. L., Bruno, L. A., Cassataro, J., & Pasquevich, K. A. (2020) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2020.10.011 · Cited by 8
Conserved antigens for enteric vaccines
Walker, R. I. (2025) · Vaccine · doi:10.1016/j.vaccine.2025.126828 · Cited by 7
Hossain, M. J., Svennerholm, A., Carlin, N., D’Alessandro, U., & Wierzba, T. F. (2023) · Microorganisms · doi:10.3390/microorganisms12010090 · Cited by 7
Coria, L. M., Martinez, F. L., Bruno, L. A., Pasquevich, K. A., & Cassataro, J. (2020) · Vaccine · doi:10.1016/j.vaccine.2020.05.039 · Cited by 7
Hossain, M. J., Secka, F., Sanyang, L. C., Taiwo, R., Okoh, E., Olubiyi, O. A., Drammeh, M., Richard-Ugwuadu, E. U., Balami, A. D., Drammeh, M., et al. (2026) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(25)00774-1 · Cited by 6
Mucosal Vaccine Development: From Adjuvant Design to Next-Generation Delivery Strategies
Lee, W.-H., & Kim, E. (2026) · Biomedicines · doi:10.3390/biomedicines14051060 · Cited by 6
Current status of mucosal vaccines against SARS-CoV2: a hope for protective immunity
García-Silva, I., Govea‐Alonso, D. O., & Rosales‐Mendoza, S. (2023) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2022.2156284 · Cited by 6
Pasetti, M. F., Milletich, P. L., White, J. A., Butts, J. K., Brady, R. C., Dickey, M., Ballou, C., Maier, N., Sztein, M. B., Baqar, S., et al. (2025) · npj Vaccines · doi:10.1038/s41541-025-01071-7 · Cited by 7
Martín-Martín, A., Tejedor, L., Tafalla, C., & Díaz‐Rosales, P. (2020) · Fish & Shellfish Immunology · doi:10.1016/j.fsi.2020.07.016 · Cited by 6
Effect of propolis on Th2 and Th17 cells: interplay with EtxB- and LPS-treated dendritic cells
Conti, B. J., Santiago, K. B., Cardoso, E. O., Conte, F. L., Golim, M. D. A., Cruz, M. T., & Sforcin, J. M. (2023) · Brazilian Journal of Medical and Biological Research · doi:10.1590/1414-431x2023e12659 · Cited by 6
Terrinoni, M., Holmgren, J. R., Turbyfill, K. R., Verg, L. V. D., Maier, N., & Walker, R. W. (2025) · Vaccines · doi:10.3390/vaccines13050513 · Cited by 5
Jung, M., Kim, H., Choi, E., Shin, M., & Shin, S. J. (2024) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2024.2317439 · Cited by 5
Global Polio Eradication: Progress and Challenges
Bandyopadhyay, A. S., & Macklin, G. (2021) · Springer eBooks · doi:10.1007/978-3-030-71165-8_30 · Cited by 8
Comparative Evaluation of Prophylactic SIV Vaccination Modalities Administered to the Oral Cavity
Chaudhary, O., Wang, L., Bose, D., Narayan, V., Yeh, M. T., Carville, A., Clements, J. D., Andino, R., Kozlowski, P. A., & Aldovini, A. (2020) · AIDS Research and Human Retroviruses · doi:10.1089/aid.2020.0157 · Cited by 5
Self-citationJia, Y., Yang, K., Sun, Q., Guo, W., Yang, Z., Duan, Z., Zhang, S., Guo, R., Ding, K., Liao, C., et al. (2025) · Vaccines · doi:10.3390/vaccines13101057 · Cited by 4
Adjuvants, immunomodulators, and adaptogens
Milicic, A., Reinke, S., Fergusson, J. R., Lindblad, E. B., Thakur, A., Corby, G., Longet, S., Górska, S., Razim, A., Hu, K., et al. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-91146-7.00009-3 · Cited by 8
Escherichia coli LTB26 mutant enhances immune responses to rotavirus antigen VP8 in a mouse model
Shi, Q., Wang, Q., Shen, Y., Chen, S., Gan, S., Lin, T., Song, F., & Ma, Y. (2024) · Molecular Immunology · doi:10.1016/j.molimm.2024.07.001 · Cited by 4
Gastric eosinophils are detrimental for Helicobacter pylori vaccine efficacy
Vaillant, L., Oster, P., McMillan, B., & Velin, D. (2021) · Vaccine · doi:10.1016/j.vaccine.2021.05.034 · Cited by 4
Park, J., & Cho, S.-H. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1152910 · Cited by 4
Barzigar, R., Haraprasad, N., Kumar, B. Y. S., & Mehran, M. J. (2020) · International Journal of Applied Pharmaceutics · doi:10.22159/ijap.2020v12i4.37722 · Cited by 4
Camp, J. V., Wilson, R. L., Singletary, M. L., Blanchard, J., Aldovini, A., Kaminski, R. W., Oaks, E. V., & Kozlowski, P. A. (2021) · Vaccine X · doi:10.1016/j.jvacx.2021.100105 · Cited by 4
Vickers, T. J., Buckley, D. P., Khatoon, N., Sheikh, A., Setu, B., Berndsen, Z. T., & Fleckenstein, J. M. (2025) · Infection and Immunity · doi:10.1128/iai.00601-24 · Cited by 3
Discovery of protease inhibitors from bacteria as novel adjuvants for oral vaccine formulations
Coria, L. M., Castro, C. P., Bruno, L. A., Nakaya, H. I., Pasquevich, K. A., & Cassataro, J. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1679540 · Cited by 3
Bhuiyan, M. S., Kalsy, A., Arifuzzaman, M., Charles, R. C., Harris, J. B., Calderwood, S. B., Qadri, F., & Ryan, E. T. (2020) · American Journal of Tropical Medicine and Hygiene · doi:10.4269/ajtmh.19-0798 · Cited by 3
Hsieh, H.-C., Chen, C.-C., Chou, P.-H., Liu, W., & Wu, S. (2023) · Antiviral Research · doi:10.1016/j.antiviral.2023.105752 · Cited by 3
Roozen, G. V. T., Sukwa, N., Chirwa, M., White, J. A., Estrada, M., Maier, N., Turbyfill, K. R., Laird, R. M., Suvarnapunya, A. E., Sayeh, A., et al. (2025) · Vaccines · doi:10.3390/vaccines13010048 · Cited by 5
Tsai, C. J., & Fujihashi, K. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-18564-9.00005-9 · Cited by 3
Zegeye, E. D., Chaukimath, P., Díaz, Y., Visweswariah, S. S., & Puntervoll, P. (2024) · Journal of Peptide Science · doi:10.1002/psc.3647 · Cited by 2
Maciel, M., Scott, J. C., Baudier, R. L., Clements, J. D., Laird, R. M., Gutiérrez, R. L., Porter, C. K., & Norton, E. B. (2025) · Medical Microbiology and Immunology · doi:10.1007/s00430-025-00817-3 · Cited by 2
Self-citationTang, N., Lin, S.-W., Chen, T., Jan, J., Wu, H., & Wu, S. (2019) · Vaccines · doi:10.3390/vaccines7040193 · Cited by 2
Identifying a stable bulk dmLT adjuvant formulation at a clinically relevant concentration
Estrada, M., Bzami, A., Norton, E. B., & White, J. A. (2023) · Vaccine · doi:10.1016/j.vaccine.2023.01.005 · Cited by 2
Self-citationPajoohian, P. F., Pind, A. A. A., Estupiñan, J. L. M., Christensen, D., Pedersen, G. K., Olafsdottir, T. A., Jónsdóttir, I., & Bjarnarson, S. P. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1563345 · Cited by 1
Immunogenicity and protection mediated by dmLT and alum adjuvants for an HIV-1 vaccine
Stokdyk, K., Sahoo, A., Gangadhara, S., Williams, L. D., Styles, T. M., Hellman, C. A., Zhang, L., Odeh, A. J., Flaherty, S., Shen, X., et al. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1706958 · Cited by 1
Self-citationGiardia unveiled: a proteome view of the parasite in search of drug, vaccine and diagnostic targets
González-López, L., Rodríguez‐Lima, O., Blancas-Luciano, B. E., Rosendo‐Pineda, M. J., Velázquez-Zavala, N. G., Vaca, L. A., Bravo, M. C., & Cruz-Reséndiz, A. (2026) · Parasitology · doi:10.1017/s0031182026101899 · Cited by 1
Bourgeois, A. L., Scott, D. A., Baqar, S., Tribble, D. R., Svennerholm, A., & Walker, R. I. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1805998 · Cited by 1
Zhao, X., Li, Z., Ma, Z., Li, Y., Li, Y., & Xiao, S. (2026) · Animals and zoonoses. · doi:10.1016/j.azn.2026.04.003 · Cited by 1
The Mucosal Immune System: An Outlook for Nanovaccines Development
Rosales‐Mendoza, S., & González‐Ortega, O. (2019) · Springer eBooks · doi:10.1007/978-3-030-31668-6_2 · Cited by 1
Desenvolvimento e uso de vacinas mucosas: Potencial e limitações
Peter, C. M., Barcelos, L. D. S., Frühauf, M. I., Botton, N. Y., Hübner, S. D. O., Lima, M. D. O., Barichello, J. M., & Fischer, G. (2021) · Research Society and Development · doi:10.33448/rsd-v10i7.16732 · Cited by 1
Tishchenko, A. S., Терехов, В. И., Pimenov, N. V., & Ivannikova, R. F. (2022) · IOP Conference Series Earth and Environmental Science · doi:10.1088/1755-1315/981/4/042067 · Cited by 1
Technologies to Improve Immunization
Zehrung, D., Jarrahian, C., & Lal, M. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-79058-1.00069-4 · Cited by 1
Edao, B. M., Upadhyay, I., & Zhang, W. (2025) · Vaccine · doi:10.1016/j.vaccine.2025.127634 · Cited by 1
Ma, Y., Shi, Q., Wang, Q., Chen, S., Gan, S., Fang, C., Shen, Y., Jiang, M., Lin, T., & Song, F. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.04.06.025981
Sandouk, A. (2022) · theses.fr (ABES) · doi:10.70675/c02c682dza047z42e4z8f19z64f35877b2d3
Is there a role for vaccines in combatting the opioid epidemic?
Norton, E. (2024) · Vaccine Insights · doi:10.18609/vac.2024.017
Self-citationStewart, J. P., & Vetro, J. A. (2024) · Springer eBooks · doi:10.1007/978-3-031-68237-7_49
Akinduti, P. A., & Oyesile, O. S. (2025) · Springer eBooks · doi:10.1007/978-3-031-86002-7_5
So, K.-K., Le, N. M. T., Nguyen, N.-L., & Kim, D.-H. (2023) · Figshare · doi:10.6084/m9.figshare.22622054
So, K.-K., Le, N. M. T., Nguyen, N.-L., & Kim, D.-H. (2023) · Figshare · doi:10.6084/m9.figshare.22622051
So, K.-K., Le, N. M. T., Nguyen, N.-L., & Kim, D.-H. (2023) · Figshare · doi:10.6084/m9.figshare.22622057
MVA-Spike encoding the A subunit of dmLT safely enhances systemic and mucosal immune responses
Rambichler, S., Kassub, R., Carrasco-León, R., Lämmermann, K., Feigl, M., Bathke, B., Durand, C., Fras, Ž., Heiseke, A. F., Riedl, A., et al. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1771410
Oral Vaccines: Recent Advances in Veterinary Medicine
Kırkan, Ş., & Polat, E. G. (2026) · Animal Health Production and Hygiene · doi:10.53913/aduveterinary.1736811
Shigella Vaccines: A Light at the End of a Long Tunnel
Walker, R. W., & Choy, R. K. M. (2026) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiag221
ETVAX: From Concepts to Demonstrated Clinical Efficacy
Svennerholm, A. (2026) · Microorganisms · doi:10.3390/microorganisms14071448
Manzoor, S. (2026) · Immunology Research and Perspectives · doi:10.64229/hbskck72
Respiratory mucosal vaccines for emerging viruses: promise and challenges
Beeton, K., & Case, J. B. (2026) · Journal of Virology · doi:10.1128/jvi.01748-25
Navigating the gastric frontier of mucosal immunity against Helicobacter pylori
Li, Y.-R., Chen, Y., Zhu, Y., Shen, X., & Yang, L. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1727910
The rise of oral vaccines in modern healthcare- An emergence of paradigm shifting
Soni, A., Khanra, B., & Sarangi, M. K. (2026) · Next Nanotechnology · doi:10.1016/j.nxnano.2026.100652
Mucosal Immunity: The Key to Combating Enteroviruses and Beyond
Kalam, N., & Balasubramaniam, V. R. M. T. (2026) · Journal of Immunology Research · doi:10.1155/jimr/4856137
Chowdhury, F., Akhtar, M., Qadri, F., & Bhuiyan, T. R. (2026) · Microorganisms · doi:10.3390/microorganisms14091956
Synthetic adjuvants to potentiate the immune response against rAg85B by nasal routePreprint
Chen, R., Tan, C., Li, W., Perera, Y., & Lobaina, Y. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.08.31.748287
Th1 and Th17 Responses to LTB and Colonization Factors Following Oral ETEC Vaccination
Kaim, J., & Lundgren, A. (2026) · Microorganisms · doi:10.3390/microorganisms14092007
Gastrointestinal Bacterial Pathogens
Simon, R., & Levine, M. M. (2026) · Springer eBooks · doi:10.1007/978-3-032-37993-1_15
Human in vitro modeling of adjuvants
Haren, S. V. (2025) · ImmPort · doi:10.21430/m3x8ftktpf
Metadata
- Authors
- Clements, J. D., & Norton, E. B.
- Affiliations
- Tulane University (US)
- Corresponding author
- Norton, Elizabeth B.
- Venue
- mSphere
- Publisher
- American Society for Microbiology
- Published
- 2018-08-29
- Volume
- 3
- Issue
- 4
- ISSN
- 2379-5042 (ISSN-L)
- PMC
- PMC6060342
- OpenAlex
- W2883931539
- Cited by
- 177
- References
- 92
- Citations by year
- 2026: 16 · 2025: 14 · 2024: 14 · 2023: 40 · 2022: 21 · 2021: 29 · 2020: 27 · 2019: 15
- FWCI
- 1.81
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0/ (vor)
- journals.asm.org/non-commercial-tdm-license (tdm)
- Locations
- mSphere (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- HHS | NIH | National Institute of Allergy and Infectious Diseases (R01AI114697, NIH2012146)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Immunology and Microbiology › Microbiology › Bacterial Infections and Vaccines
- Life Sciences › Immunology and Microbiology › Immunology › Immune responses and vaccinations
- Keywords
- cholera toxin B subunit, mucosal immunization, IgA antibodies, Th1/Th2/Th17 responses, cytotoxic T lymphocytes, adjuvant mechanisms, preclinical and clinical trials, vaccine formulation
- MeSH terms
- Adjuvants, Immunologic, Bacterial Toxins, Enterotoxins, Vaccines, Protein Subunits, Escherichia coli Proteins, Mutant Proteins, Administration, Mucosal
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.

